AVEO Oncology Presents TiNivo-2 Results and TIVO-3 Exploratory Post Immunotherapy Survival Analysis at ESMO 2024
Monday, 16 September 2024, 05:10
Key Findings from TiNivo-2
AVEO Oncology, an LG Chem company, recently presented the results of the TiNivo-2 Phase 3 clinical trial at ESMO 2024. This trial focused on patients with advanced metastatic renal cell carcinoma (RCC) who experienced tumor progression.
Significance of the Results
- Survival Rates: The TiNivo-2 results demonstrated improved survival rates among participants, emphasizing the impact of immunotherapy in treating RCC.
- Clinical Implications: Such findings could potentially alter treatment protocols and improve patient outcomes in oncology.
TIVO-3 Exploratory Analysis
Moreover, the TIVO-3 exploratory study provided further insights into post-immunotherapy survival, contributing valuable data to ongoing research.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.